Display options
Cite
Pietschke K, Holstein J, Meier K, et al. The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition. Exp Dermatol. 2020;30(2):262-270doi: 10.1111/exd.14226.
Pietschke, K., Holstein, J., Meier, K., Schäfer, I., Müller-Hermelink, E., Gonzalez-Menendez, I., Quintanilla-Martinez, L., Ghoreschi, F. C., Solimani, F., & Ghoreschi, K. (2021). The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition. Experimental dermatology, 30(2), 262-270. https://doi.org/10.1111/exd.14226
Pietschke, Katharina, et al. "The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition." Experimental dermatology vol. 30,2 (2021): 262-270. doi: https://doi.org/10.1111/exd.14226
Pietschke K, Holstein J, Meier K, Schäfer I, Müller-Hermelink E, Gonzalez-Menendez I, Quintanilla-Martinez L, Ghoreschi FC, Solimani F, Ghoreschi K. The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition. Exp Dermatol. 2021 Feb;30(2):262-270. doi: 10.1111/exd.14226. Epub 2020 Nov 12. PMID: 33113249.
Copy Download .nbib Format: NLM
Share it on

Exp Dermatol. 2021 Feb;30(2):262-270. doi: 10.1111/exd.14226. Epub 2020 Nov 12.

The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition.

Experimental dermatology

Katharina Pietschke, Julia Holstein, Katharina Meier, Iris Schäfer, Eva Müller-Hermelink, Irene Gonzalez-Menendez, Leticia Quintanilla-Martinez, Franziska C Ghoreschi, Farzan Solimani, Kamran Ghoreschi

Affiliations

  1. Department of Dermatology, University Medical Center Tübingen, Eberhard Karls University, Tubingen, Germany.
  2. Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  3. Institute of Pathology and Neuropathology, Eberhard Karls University of Tubingen and Comprehensive Cancer Center, Tubingen University Hospital, Tubingen, Germany.

PMID: 33113249 DOI: 10.1111/exd.14226

Abstract

Cutaneous lichen planus (CLP) and psoriasis (PSO) are both common chronic inflammatory skin diseases for which development of new treatments requires the identification of key targets. While PSO is a typical Th17/IL-17-disorder, there is some evidence that Th1/IFN-ɣ dominate the inflammatory process in CLP. Nonetheless, the immunopathogenesis of CLP is not fully explained and key immunological factors still have to be recognized. In this study, we compared the immune signature of CLP lesions with the well-characterized inflammation present in PSO skin. First, we analysed the histological and immunohistological characteristics of CLP and PSO. Second, we assessed the cytokine expression (IL1A, IL1B, IL4, IL6, IL8, IL10, IL17A, IL19, IL21, IL22, IL23A, IL13, IFNG, TNF, IL12A, IL12B and IL36G) of lesional skin of CLP with PSO by qPCR. Histology revealed a similar epidermal thickness in CLP and PSO. Immunohistochemically, both diseases presented with an inflammatory infiltrate mainly composed by CD3

© 2020 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.

Keywords: IL-17; JAK inhibitors; immune signature; lichen planus; psoriasis

References

  1. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35. - PubMed
  2. Van Cranenburgh OD, Nijland SB, De Korte J, et al. Satisfaction with treatment and health-related quality of life among patients with lichen planus: a web-based survey. Eur J Dermatol. 2016;26(1):113-116. - PubMed
  3. Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med. 2012;366(8):723-732. - PubMed
  4. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. - PubMed
  5. Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003;9(1):40-46. - PubMed
  6. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-255. - PubMed
  7. Sabat R, Wolk K, Loyal L, Docke WD, Ghoreschi K. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41(3):359-377. - PubMed
  8. Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. - PubMed
  9. Solimani F, Hilke FJ, Ghoreschi K. Pharmacology of Janus kinase inhibitors. Hautarzt. 2019;70(12):934-941. - PubMed
  10. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525-1536. - PubMed
  11. Ioannides D, Vakirlis E, Kemeny L, et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2020;34(7):1403-1414. - PubMed
  12. Schmidt T, Solimani F, Pollmann R, et al. TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. J Allergy Clin Immunol. 2018;142(2):669-672. - PubMed
  13. Shao S, Tsoi LC, Sarkar MK, et al. IFN-gamma enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med. 2019;11(511):eaav7561. - PubMed
  14. Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol. 2016;175(5):892-901. - PubMed
  15. Wang K, Miao T, Lu W, et al. Analysis of oral microbial community and Th17-associated cytokines in saliva of patients with oral lichen planus. Microbiol Immunol. 2015;59(3):105-113. - PubMed
  16. Lu R, Zeng X, Han Q, et al. Overexpression and selectively regulatory roles of IL-23/IL-17 axis in the lesions of oral lichen planus. Mediators Inflamm. 2014;2014:701094. - PubMed
  17. Javvadi LR, Parachuru VP, Milne TJ, Seymour GJ, Rich AM. Regulatory T-cells and IL17A(+) cells infiltrate oral lichen planus lesions. Pathology. 2016;48(6):564-573. - PubMed
  18. Hobo A, Harada K, Maeda T, et al. IL-17-positive mast cell infiltration in the lesional skin of lichen planopilaris: Possible role of mast cells in inducing inflammation and dermal fibrosis in cicatricial alopecia. Exp Dermatol. 2020;29(3):273-277. - PubMed
  19. Ismail FF, Sinclair R. Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin-23/interleukin-17 pathway in the pathogenesis of lichen planus. Australas J Dermatol. 2019;61(2):e244e245. - PubMed
  20. Knisley RR, Petropolis AA, Mackey VT. Lichen planus pemphigoides treated with ustekinumab. Cutis. 2017;100(6):415-418. - PubMed
  21. Solimani F, Pollmann R, Schmidt T, et al. Therapeutic targeting of Th17/Tc17 cells leads to clinical improvement of Lichen Planus. Front Immunol. 2019;10:1808. - PubMed
  22. Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163(6):1282-1290. - PubMed
  23. Sticherling M, Sautier W, Schroder JM, Christophers E. Interleukin-8 plays its role at local level in psoriasis vulgaris. Acta Derm Venereol. 1999;79(1):4-8. - PubMed
  24. D'Erme AM, Wilsmann-Theis D, Wagenpfeil J, et al. IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol. 2015;135(4):1025-1032. - PubMed
  25. Rajarathnam K, Sykes BD, Kay CM, et al. Neutrophil activation by monomeric interleukin-8. Science. 1994;264(5155):90-92. - PubMed
  26. Duan H, Koga T, Kohda F, Hara H, Urabe K, Furue M. Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci. 2001;26(2):119-124. - PubMed
  27. Steffen S, Abraham S, Herbig M, et al. Toll-like receptor-mediated upregulation of CXCL16 in psoriasis orchestrates neutrophil activation. J Invest Dermatol. 2018;138(2):344-354. - PubMed
  28. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428-2437. - PubMed
  29. Revu S, Wu J, Henkel M, et al. IL-23 and IL-1beta drive human Th17 cell differentiation and metabolic reprogramming in absence of CD28 costimulation. Cell Rep. 2018;22(10):2642-2653. - PubMed
  30. Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature. 2010;467(7318):967-971. - PubMed
  31. Gonzalez N, Patel P, Han G. A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar. Br J Dermatol. 2018;178(4):965-968. - PubMed
  32. Maglie R, Di Cesare A, Lazzeri L, et al. Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment. Br J Dermatol. 2018;178(1):303-304. - PubMed
  33. Wenzel J, Scheler M, Proelss J, Bieber T, Tuting T. Type I interferon-associated cytotoxic inflammation in lichen planus. J Cutan Pathol. 2006;33(10):672-678. - PubMed
  34. Wenzel J, Peters B, Zahn S, et al. Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis. J Invest Dermatol. 2008;128(1):67-78. - PubMed
  35. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170-181. - PubMed
  36. Shen Z, Gao X, Ma L, Zhou Z, Shen X, Liu W. Expression of Foxp3 and interleukin-17 in lichen planus lesions with emphasis on difference in oral and cutaneous variants. Arch Dermatol Res. 2014;306(5):441-446. - PubMed
  37. de Boer OJ, van der Loos CM, Teeling P, van der Wal AC, Teunissen MB. Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem. 2007;55(9):891-898. - PubMed
  38. Chang HD, Helbig C, Tykocinski L, et al. Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3. Eur J Immunol. 2007;37(3):807-817. - PubMed
  39. Onderdijk AJ, Baerveldt EM, Kurek D, et al. IL-4 Downregulates IL-1beta and IL-6 and induces GATA3 in psoriatic epidermal cells: route of action of a Th2 cytokine. J Immunol. 2015;195(4):1744-1752. - PubMed
  40. Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50(4):907-923. - PubMed
  41. Gallais Serezal I, Hoffer E, Ignatov B, et al. A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis. J Allergy Clin Immunol. 2019;143(4):1444-1454. - PubMed
  42. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol. 2011;131(2):391-400. - PubMed
  43. Shaker OG, Hantar N, El-Tahlawi S, et al. Detection of myxovirus resistance protein A in lichen planus lesions and its relationship to hepatitis C virus. Br J Dermatol. 2009;160(5):980-983. - PubMed
  44. Shaker O, Hassan AS. Possible role of interleukin-17 in the pathogenesis of lichen planus. Br J Dermatol. 2012;166(6):1367-1368. - PubMed
  45. Gueiros LA, Arao T, Souza T, et al. IL17A polymorphism and elevated IL17A serum levels are associated with oral lichen planus. Oral Dis. 2018;24(3):377-383. - PubMed
  46. Kastirr I, Maglie S, Paroni M, et al. IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells. J Immunol. 2014;193(7):3322-3331. - PubMed
  47. Carbone T, Nasorri F, Pennino D, et al. CD56 highCD16 - NK cell involvement in cutaneous lichen planus. Eur J Dermatol. 2010;20(6):724-730. - PubMed
  48. Tian Y, Zajac AJ. IL-21 and T cell differentiation: consider the context. Trends Immunol. 2016;37(8):557-568. - PubMed
  49. Tan YQ, Li Q, Zhang J, Du GF, Lu R, Zhou G. Increased circulating CXCR5(+) CD4(+) T follicular helper-like cells in oral lichen planus. J Oral Pathol Med. 2017;46(9):803-809. - PubMed
  50. Craft JE. Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol. 2012;8(6):337-347. - PubMed
  51. Solaymani-Mohammadi S, Berzofsky JA. Interleukin 21 collaborates with interferon-gamma for the optimal expression of interferon-stimulated genes and enhances protection against enteric microbial infection. PLoS Pathog. 2019;15(2):e1007614. - PubMed
  52. Strengell M, Matikainen S, Siren J, et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol. 2003;170(11):5464-5469. - PubMed
  53. Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11(10):e0164080. - PubMed
  54. Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J Allergy Clin Immunol. 2020;145:1708-1710.e2. - PubMed
  55. Yang CC, Khanna T, Sallee B, Christiano AM, Bordone LA. Tofacitinib for the treatment of lichen planopilaris: A case series. Dermatol Ther. 2018;31(6):e12656. - PubMed
  56. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009;9(7):480-490. - PubMed
  57. Viguier M, Bachelez H, Poirier B, et al. Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus. J Invest Dermatol. 2015;135(2):418-424. - PubMed

Publication Types